The Vernal Keratoconjunctivitis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Vernal Keratoconjunctivitis: An Overview
Vernal keratoconjunctivitis (VKC) is a bilateral, usually seasonally recurrent, allergic inflammation of the conjunctiva, characterized by limbal gelatinous hypertrophy and/or upper tarsal giant conjunctival papillae. It is an IgE-mediated and T-cell-mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte, and structural cell activation are involved. The disease may present in three clinical forms: tarsal, limbal, and mixed form. It characteristically affects young males in hot dry climates in a seasonal manner; however, this is not always the rule.
Vernal Keratoconjunctivitis is more prevalent in dry hot climates, specifically in the Mediterranean Basin, the Middle East, Central and West Africa, India, and South America. It affects more frequently in males than females.
Currently, there is no defined standard treatment algorithm for Vernal Keratoconjunctivitis, but there are many options available, and treatment should be tailored to the individual. Individuals treated should be monitored closely for the development of any corneal complications. The current treatment options include mast cell stabilizers, antihistamines, nonsteroidal anti-inflammatory drugs (NSAIDs), topical corticosteroids, cyclosporine, and tacrolimus.
Vernal Keratoconjunctivitis Market Key Facts
The prevalence, as well as the type, of Vernal Keratoconjunctivitis, varies depending on geographic region, e.g. the palpebral form is most frequent in Europe and the US.
The total prevalent population of Vernal Keratoconjunctivitis (VKC) in the 7MM was observed to be 620,585 in 2021.
The estimates show that the prevalence of Vernal Keratoconjunctivitis in the United States was observed to be 67,389 cases in the year 2021.
Out of the total diagnosed cases, Mild includes 35.90% cases, Moderate includes 40.60%, and Severe includes 23.50% in 2021 in the United States.
Japan had 220,842 diagnosed prevalent cases of Vernal Keratoconjunctivitis in 2021.
The majority of Vernal Keratoconjunctivitis occurs in patients between the ages of 0–20 years old with an age of onset between 10–12 years old; however, there are reports of patients as young as 5 months old.
Among the EU4 and the UK countries, Italy had the highest prevalent population of Vernal Keratoconjunctivitis with 173,432 cases, followed by Germany and France. On the other hand, Spain had the lowest prevalent population of 16,072 in 2021.
As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for males, in comparison to females, in all the 7MM during the study period.
Vernal Keratoconjunctivitis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Vernal Keratoconjunctivitis market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Vernal Keratoconjunctivitis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Vernal Keratoconjunctivitis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Vernal Keratoconjunctivitis Epidemiology, Segmented as –
Total Prevalent Population of VKC in the 7MM (2019-32)
Diagnosed Prevalent Population of VKC in the 7MM (2019-32)
Gender-specific Diagnosed Prevalent Population of VKC in the 7MM (2019-32)
Type-specific Diagnosed Prevalent Population of VKC in the 7MM (2019-32)
Severity-specific Diagnosed Prevalent Population of VKC in the 7MM (2019-32)
Age-specific Diagnosed Prevalent Population of VKC in the 7MM (2019-32)
Vernal Keratoconjunctivitis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Vernal Keratoconjunctivitis market or expected to be launched during the study period. The analysis covers the Vernal Keratoconjunctivitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Vernal Keratoconjunctivitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Vernal Keratoconjunctivitis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market-insight
Vernal Keratoconjunctivitis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Vernal Keratoconjunctivitis. Currently, iCo Therapeutics is leading the therapeutics market with its Vernal Keratoconjunctivitis drug candidates in the most advanced stage of clinical development.
Leading Players in the Vernal Keratoconjunctivitis Therapeutics Market Include
iCo Therapeutics
Vanda Pharmaceuticals
Sylentis
Allakos
And Many Others
Vernal Keratoconjunctivitis Emerging and Marketed Drugs Covered in the Report Include:
Bertilimumab/iCo-008: iCo Therapeutics
Verkazia/Verkacia: Santen
Lodoxamide/Alomide: Novartis Pharmaceuticals/Alcon
Talymus/Tacrolimus: Senju Pharmaceutical
Antolimab (AK002): Allakos
Nomacopan: Akari Therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Vernal Keratoconjunctivitis Competitive Intelligence Analysis
4. Vernal Keratoconjunctivitis Market Overview at a Glance
5. Vernal Keratoconjunctivitis Disease Background and Overview
6. Vernal Keratoconjunctivitis Patient Journey
7. Vernal Keratoconjunctivitis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Vernal Keratoconjunctivitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Vernal Keratoconjunctivitis Unmet Needs
10. Key Endpoints of Vernal Keratoconjunctivitis Treatment
11. Vernal Keratoconjunctivitis Marketed Products
12. Vernal Keratoconjunctivitis Emerging Drugs and Latest Therapeutic Advances
13. Vernal Keratoconjunctivitis Seven Major Market Analysis
14. Attribute Analysis
15. Vernal Keratoconjunctivitis Market Outlook (In US, EU5, and Japan)
16. Vernal Keratoconjunctivitis Access and Reimbursement Overview
17. KOL Views on the Vernal Keratoconjunctivitis Market
18. Vernal Keratoconjunctivitis Market Drivers
19. Vernal Keratoconjunctivitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports by DelveInsight
Polypoidal Choroidal Vasculopathy (PCV) Market
“Polypoidal Choroidal Vasculopathy (PCV) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Polypoidal Choroidal Vasculopathy market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Polypoidal Choroidal Vasculopathy market.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
